Search
Bertilimumab
go.drugbank.com/drugs/DB05429InvestigationalBertilimumab is a fully human anti-eotaxin monoclonal antibody with potential in the treatment of allergic disorders, has moved into pre-clinical development.
Phosmet
go.drugbank.com/drugs/DB11448ExperimentalVet approvedIt is mainly used on apple trees to control codling moths. It is also used on other fruit crops, ornamentals, and vines to control aphids, suckers, mites, and fruit flies.
Categories: Compounds used in a research, industrial, or household settingL-aminocarnityl-succinyl-leucyl-argininal-diethylacetal
go.drugbank.com/drugs/DB06124ExperimentalC-101, also called Myodur, is developed for the treatment of Duchenne’s muscular dystrophy (DMD) which is a morbid genetic disease that can lead to death in late adolescence due to accelerated skeletal
Proteasome subunit beta type-6
go.drugbank.com/bio_entities/BE0003919TargetHumansComponent of the 20S core proteasome complex involved in the proteolytic degradation of most intracellular proteins. … This type of proteolysis is required in several pathways including spermatogenesis (20S-PA200 complex) or generation of a subset of MHC class I-presented antigenic peptides (20S-PA28 complex).
Synonyms: Multicatalytic endopeptidase complex delta chainChlorocresol
go.drugbank.com/drugs/DB16864InvestigationalCategories: Compounds used in a research, industrial, or household settingGoralatide
go.drugbank.com/drugs/DB20748ExperimentalGoralatide is a small molecule drug. Goralatide has a monoisotopic molecular weight of 487.23 Da.
Categories: Compounds used in a research, industrial, or household settingMagaldrate
go.drugbank.com/drugs/DB08938ApprovedInvestigationalWithdrawnMagaldrate is an antacid drug used for the treatment of esophagitis, duodenal and gastric ulcers, and gastroesophageal reflux. Magaldrate has been discontinued in the US market.
PSN9301
go.drugbank.com/drugs/DB05001ExperimentalPSN9301 is an oral small molecule inhibitor of Dipeptidyl Peptidase IV (DP-IV), being developed for the treatment of type 2 diabetes. … PSN9301 has a very rapid onset and a relatively short duration of action, and available pre-clinical and clinical data indicate that it may be an ideal product candidate for meal-related dosing.
Pracinostat
go.drugbank.com/drugs/DB05223InvestigationalPracinostat is a novel HDAC inhibitor with improved in vivo properties compared to other HDAC inhibitors currently in clinical trials, allowing oral dosing. … Data demonstrate that Pracinostat is a potent and effective anti-tumor drug with potential as an oral therapy for a variety of human hematological and solid tumors.
LY2275796
go.drugbank.com/drugs/DB05165InvestigationalLY2275796 targets eukaryotic initiation factor- 4E (eIF-4E), a protein involved in the translation of key growth and survival factors that drive tumor progression, angiogenesis and metastases.